- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Subfoveal choroidal neovascularisation (CNV)
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 942KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 63KB)
Brolucizumab – July 2020
Brolucizumab: Solution for intravitreal injection 19.8 mg in 0.165 mL pre-filled syringe; Beovu®
Last updated
30 October 2020